PMC:7346000 / 28794-29036 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T63","span":{"begin":85,"end":90},"obj":"Body_part"}],"attributes":[{"id":"A63","pred":"fma_id","subj":"T63","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T33","span":{"begin":85,"end":90},"obj":"Body_part"}],"attributes":[{"id":"A33","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}

{"project":"LitCovid-PubTator","denotations":[{"id":"781","span":{"begin":18,"end":26},"obj":"Disease"}],"attributes":[{"id":"A781","pred":"tao:has_database_id","subj":"781","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T237","span":{"begin":18,"end":26},"obj":"Disease"}],"attributes":[{"id":"A237","pred":"mondo_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T225","span":{"begin":85,"end":90},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T226","span":{"begin":85,"end":90},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T194","span":{"begin":38,"end":41},"obj":"Chemical"},{"id":"T196","span":{"begin":78,"end":81},"obj":"Chemical"},{"id":"T198","span":{"begin":238,"end":241},"obj":"Chemical"}],"attributes":[{"id":"A194","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A195","pred":"chebi_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A196","pred":"chebi_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A197","pred":"chebi_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A198","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A199","pred":"chebi_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T57","span":{"begin":38,"end":41},"obj":"Phenotype"},{"id":"T58","span":{"begin":78,"end":81},"obj":"Phenotype"},{"id":"T59","span":{"begin":238,"end":241},"obj":"Phenotype"}],"attributes":[{"id":"A57","pred":"hp_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A58","pred":"hp_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A59","pred":"hp_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}

{"project":"LitCovid-sentences","denotations":[{"id":"T159","span":{"begin":0,"end":242},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In settings where COVID-19 associated IPA occurs most commonly, screening for IPA in blood and true BALF samples (i.e., obtained via bronchoscopy) will be implemented followed by preemptive treatment in those with mycological evidence of IPA."}